Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
PaySign Inc is a software-infrastructure business based in the US. PaySign shares (PAYS) are listed on the NASDAQ and all prices are listed in US Dollars. PaySign employs 70 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Guided investing
Our top pick for
Building a portfolio
Our top pick for
Beginners
| Latest market close | $1.80 |
|---|---|
| 52-week range | $1.37 - $5.69 |
| 50-day moving average | $1.89 |
| 200-day moving average | $2.75 |
| Wall St. target price | $4.00 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-0.15 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.8 from 2022-01-19
| 1 week (2022-01-13) | -7.69% |
|---|---|
| 1 month (2021-12-20) | 20.81% |
| 3 months (2021-10-20) | -31.03% |
| 6 months (2021-07-20) | -30.50% |
| 1 year (2021-01-20) | -62.96% |
|---|---|
| 2 years (2020-01-17) | -80.83% |
| 3 years (2019-01-18) | 4.18 |
| 5 years (2017-01-20) | 453.85% |
Valuing PaySign stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of PaySign's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
PaySign's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $6.3 million.
The EBITDA is a measure of a PaySign's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $28 million |
|---|---|
| Gross profit TTM | $9.3 million |
| Return on assets TTM | -2.84% |
| Return on equity TTM | -49.1% |
| Profit margin | -25.54% |
| Book value | $0.24 |
| Market capitalisation | $100.3 million |
TTM: trailing 12 months
We're not expecting PaySign to pay a dividend over the next 12 months.
PaySign's shares were split on a 1:20 basis on 30 October 2005. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your PaySign shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for PaySign shares which in turn could have impacted PaySign's share price.
Over the last 12 months, PaySign's shares have ranged in value from as little as $1.37 up to $5.69. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while PaySign's is 1.1622. This would suggest that PaySign's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
PaySign, Inc. provides prepaid card products and processing services under the PaySign brand for corporate, consumer, and government applications. The company offers various services, including transaction processing, cardholder enrollment, value loading, cardholder account management, reporting, and customer service through PaySign, a proprietary card-processing platform. It also develops prepaid card solutions for corporate incentive and rewards, consumer rebates, donor compensation, clinical trials, healthcare reimbursement payments, and pharmaceutical payment assistance; and payroll or general purpose reloadable cards, as well as gift or incentive cards. In addition, the company offers Co-Pay Assistance Program, a pharmaceutical payment card product; and Per Diem/Corporate Expense Payments that allows businesses, and non?profits and government agencies the ability to control employee spending while reducing administration costs by eliminating the need for traditional expense reports. Further, it provides Buy and Bill programs for patients to purchase directly from physician's office or through an infusion center for physician administered therapies; payment solution for source plasma collection centers; and PaySign Premier, a demand deposit account debit card, as well as customer service center and PaySign Communications Suite services. Its principal target markets for processing services comprise prepaid card issuers, retail and private-label issuers, small third-party processors, and small and mid-size financial institutions in the United States and internationally.
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.
Everything we know about the Austin Gold IPO, plus information on how to buy in.
Everything we know about the VinFast IPO, plus information on how to buy in.
Everything we know about the Nexalin Technology IPO, plus information on how to buy in.
Everything we know about the Specialty Building Products IPO, plus information on how to buy in.
Everything we know about the HeartCore Enterprises IPO, plus information on how to buy in.
Everything we know about the Credo Technology Group Holding IPO, plus information on how to buy in.
Everything we know about the Hongli Group IPO, plus information on how to buy in.
Everything we know about the Reborn Coffee IPO, plus information on how to buy in.
